Immunome Reports First Quarter 2024 Financial Results and Provides Business Update BOTHELL, Wash. – Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in- class targeted cancer therapies, today announced financial results for the first quarter ended March 31, 2024, and provided a business update. Exhibit 99.1 "Immunome continues to build momentum. We have completed the integration of AL102 and are executing activities necessary for regulatory submissions," s ...

Immunome, Inc. (IMNM) is expected to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended March 2024. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.The stock might move higher if these key numbers top expectations in the upcoming earnings report. On the other hand, if they miss, the stock ma ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-39580 IMMUNOME, INC. (Exact name of registrant as specified in its charter) Delaware 77-0694340 (State of Other Jurisdiction of incorporation or Organization) ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39580 Immunome, Inc. (Exact name of registrant as specified in its charter) Delaware 77-0694340 (State or ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39580 Immunome, Inc. (Exact name of registrant as specified in its charter) Delaware 77-0694340 (State or othe ...

Table of Contents For the transition period from to Commission File Number: 001-39580 Immunome, Inc. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (Exact name of registrant as specified in its charter) Delaware 77-0694340 (State or oth ...

Oncology and Therapeutics Development - The company has identified over 1,000 individual antibodies, referred to as "hits," with high-affinity binding to cancer cells or tumor extracts, leading to the identification of over 70 potentially novel cancer targets[23]. - The lead oncology program, IMM-ONC-01, targets IL-38, with plans to submit an IND application to the FDA by mid-2023[39]. - The company aims to leverage insights from over 70 identified cancer targets to guide future oncology pipeline assets and strategic collaborations[24]. - The company is focused on developing antibody therapeutics for oncology and infectious diseases, utilizing a proprietary human memory B cell platform[22]. - The company plans to submit an IND for the IMM-ONC-01 program by mid-2023, but there are no assurances that this will occur as anticipated[195]. - The company has decided to seek a partner for the IMM-BCP-01 program to continue its Phase 1b trial and further development activities[203]. Clinical Trials and Regulatory Compliance - The Phase 1b study of IMM-BCP-01 successfully completed dosing of the first cohort of patients with no significant treatment-related adverse events as of January 6, 2023[40]. - Clinical trials must be conducted under protocols detailing study objectives, safety monitoring parameters, and effectiveness criteria[91]. - The FDA requires sponsors of Phase 3 clinical trials to submit a diversity action plan, including enrollment goals and rationale[100]. - The FDA may require additional Phase 4 studies post-approval to gather more information about a product[96]. - The company must submit results of preclinical studies, manufacturing information, and proposed clinical protocols to the FDA as part of the IND application[89]. - The company may face significant delays in advancing its programs and development candidates through clinical development and obtaining regulatory approval[192]. Financial Performance and Funding - As of December 31, 2022, the company had an accumulated deficit of $116.0 million and reported a net loss of $36.9 million for the year ended December 31, 2022[183]. - The company has not generated any revenue from product sales and does not expect to do so for the foreseeable future[185]. - The company expects net losses to increase substantially as operations continue, with future losses being uncertain[186]. - The research and development of biopharmaceutical products is capital-intensive, and the company will need substantial additional funds to expand its capabilities[187]. - The company has used substantial funds to develop its discovery engine and will require significant funds for further research and development[187]. Intellectual Property and Licensing - The company plans to expand its intellectual property estate and may pursue both therapeutic and diagnostic applications of its antibodies[44]. - The company owns 68 pending national phase patent applications in the U.S. and abroad, three pending PCT applications, and seven pending U.S. provisional patent applications, covering a total of 12 patent families[74]. - The company has a layered patent estate that it believes provides substantial intellectual property protection, including methods of treatment for diseases expressing novel targets[73]. - The company is required to navigate various preclinical, clinical, and commercial approval requirements set by regulatory agencies for its programs and development candidates[86]. Collaborations and Partnerships - The Company entered into a collaboration agreement with AbbVie, which includes an upfront payment of $30 million and potential total payments of up to $2.8 billion based on various milestones and royalties[48][50]. - AbbVie will pay additional platform access payments of up to $70 million based on the Company's use of its discovery engine and delivery of validated target pairs (VTPs)[48]. - The Company is exploring strategic collaborations and licensing agreements to maximize the value of its platform and programs[46]. Challenges and Risks - The five-year survival rate for patients with advanced malignancies remains below 10%, highlighting the need for innovative cancer therapeutics[28]. - The company may face challenges in obtaining reimbursement for its products due to higher prices associated with branded drugs and the need for extensive pharmacoeconomic studies[161]. - Delays in clinical trials may arise from various factors, including regulatory approvals, participant recruitment challenges, and manufacturing process issues[209][210]. - The company anticipates that competition for clinical trial participants may reduce the number available for its trials, impacting enrollment[211]. Government Regulations and Market Access - Coverage and adequate reimbursement from governmental health care programs are critical to new product acceptance[158]. - The company is subject to various pricing and reimbursement regulations, which may impact the marketability of its products[165]. - The Inflation Reduction Act of 2022 requires manufacturers to pay rebates if drug prices increase faster than inflation, starting in 2023[172]. - The FDA closely regulates marketing and promotion of biologics, allowing only claims that are approved and in accordance with the product's labeling[135].

PART I – FINANCIAL INFORMATION Presents unaudited financial statements, management's discussion, market risk, and controls for the period [Financial Statements (Unaudited)](index=4&type=section&id=Item%201.%20Financial%20Statements%20%28Unaudited%29) Presents unaudited condensed financial statements for Immunome, Inc., detailing financial position, operations, and cash flows [Condensed Balance Sheets](index=4&type=section&id=Condensed%20Balance%20Sheets) Details assets, liabilities, and equity, showing decreased cash and total assets, and increased accumulated deficit due to ongoing net losses Condensed Balance Sheets | Account | Sep 30, 2022 ($ thousands) | Dec 31, 2021 ($ thousands) | | :--- | :--- | :--- | | **Assets** | | | | Cash and cash equivalents | 27,078 | 49,229 | | Total current assets | 29,239 | 56,638 | | Total assets | 30,546 | 57,925 | | **Liabilities & Equity** | | | | Total liabilities | 7,462 | 9,740 | | Accumulated deficit | (108,215) | (79,105) | | Total stockholders' equity | 23,084 | 48,185 | [Condensed Statements of Operations](index=5&type=section&id=Condensed%20Statements%20of%20Operations) Reports a significant increase in net loss to **$29.1 million**, primarily due to higher research and development expenses Condensed Statements of Operations | Metric | Nine Months Ended Sep 30, 2022 ($ thousands) | Nine Months Ended Sep 30, 2021 ($ thousands) | | :--- | :--- | :--- | | Research and development | 19,020 | 9,725 | | General and administrative | 10,094 | 7,635 | | Total operating expenses | 29,114 | 17,360 | | Loss from operations | (29,114) | (17,360) | | Net loss | (29,110) | (16,859) | | Net loss per share | (2.45) | (1.49) | [Condensed Statements of Cash Flows](index=7&type=section&id=Condensed%20Statements%20of%20Cash%20Flows) Shows a near doubling of cash used in operations and a significant decrease in cash from financing activities, resulting in a net cash decrease Condensed Statements of Cash Flows | Cash Flow Activity | Nine Months Ended Sep 30, 2022 ($ thousands) | Nine Months Ended Sep 30, 2021 ($ thousands) | | :--- | :--- | :--- | | Net cash used in operating activities | (22,007) | (11,421) | | Net cash used in investing activities | (176) | (65) | | Net cash provided by financing activities | 32 | 27,963 | | Net (decrease) increase in cash | (22,151) | 16,477 | | Cash at end of period | 27,178 | 56,343 | [Notes to Condensed Financial Statements](index=8&type=section&id=Notes%20to%20Condensed%20Financial%20Statements) Provides detailed context on the company's financial position, operations, capital raising, and significant transactions like warrant modification - The company is a clinical-stage biopharmaceutical firm focusing on oncology and infectious diseases, including COVID-19, and has incurred net losses since inception, expecting them to continue[21](index=21&type=chunk)[23](index=23&type=chunk) - As of September 30, 2022, the company had **$27.1 million** in cash and cash equivalents, believed to be sufficient to fund operations for at least 12 months from the report's filing date[25](index=25&type=chunk) - In July 2020, the company entered into a U.S. Department of Defense (DoD) agreement for up to **$17.6 million** in funding for its COVID-19 antibody therapeutic development, with **$17.4 million** received as of September 30, 2022[59](index=59&type=chunk)[62](index=62&type=chunk) - On September 2, 2022, the company modified its Series B Warrants, reducing the exercise price from **$45.00 to $10.00** per share, resulting in a non-cash deemed dividend of **$0.6 million**[83](index=83&type=chunk) [Management's Discussion and Analysis of Financial Condition and Results of Operations](index=28&type=section&id=Item%202.%20Management%27s%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations.) Management discusses financial performance, liquidity, and operational progress, highlighting increased net loss, program advancements, and future funding needs - The company's lead COVID-19 program, IMM-BCP-01, initiated a Phase 1b study in June 2022, with topline safety and PK data expected by the end of 2022[108](index=108&type=chunk)[109](index=109&type=chunk) - The lead oncology program, IMM-ONC-01, targeting IL-38, is advancing towards clinical trials, with plans to submit an IND application by mid-2023[110](index=110&type=chunk) Expense Category Changes | Expense Category | Nine Months Ended Sep 30, 2022 ($M) | Nine Months Ended Sep 30, 2021 ($M) | Change ($M) | Primary Driver of Change | | :--- | :--- | :--- | :--- | :--- | | Research & Development | 19.0 | 9.7 | +9.3 | $12.7M reduction in contra-R&D expense from DoD contract, partially offset by lower outsourced research costs | | General & Administrative | 10.1 | 7.6 | +2.5 | $2.5M increase in personnel-related costs due to higher headcount and stock-based compensation | - The company expects its cash of **$27.1 million** as of September 30, 2022, will be sufficient to fund operations for at least 12 months from the filing date, but substantial additional financing will be required for long-term strategy[107](index=107&type=chunk)[142](index=142&type=chunk) [Quantitative and Qualitative Disclosures about Market Risk](index=50&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20about%20Market%20Risk.) As a smaller reporting company, Immunome, Inc. is not required to provide quantitative and qualitative market risk disclosures - The company is not required to provide quantitative and qualitative disclosures about market risk because it qualifies as a smaller reporting company[172](index=172&type=chunk) [Controls and Procedures](index=50&type=section&id=Item%204.%20Controls%20and%20Procedures.) Management concluded disclosure controls were effective, with no material changes to internal control over financial reporting during the quarter - Management concluded that as of September 30, 2022, the company's disclosure controls and procedures were effective[175](index=175&type=chunk) - No material changes in internal control over financial reporting occurred during the quarter ended September 30, 2022[176](index=176&type=chunk) PART II – OTHER INFORMATION Covers legal proceedings, risk factors, equity sales, and required exhibits for the reporting period [Legal Proceedings](index=52&type=section&id=Item%201.%20Legal%20Proceedings.) The company reports it is not currently a party to any material legal proceedings - The company is not currently involved in any material legal proceedings[178](index=178&type=chunk) [Risk Factors](index=52&type=section&id=Item%201A.%20Risk%20Factors.) As a smaller reporting company, Immunome, Inc. is not required to provide risk factor disclosures - The company is not required to provide risk factor disclosures in its Form 10-Q as it is a smaller reporting company[179](index=179&type=chunk) [Unregistered Sales of Equity Securities and Use of Proceeds](index=52&type=section&id=Item%202.%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds.) The company reported no unregistered sales of equity securities or use of proceeds during the period - There were no unregistered sales of equity securities or use of proceeds to report for the period[180](index=180&type=chunk) [Exhibits](index=53&type=section&id=Item%206.%20Exhibits.) Lists exhibits filed with the Form 10-Q, including CEO and CFO certifications and interactive data files - Exhibits filed with the report include certifications from the CEO and CFO pursuant to Sections 302 and 906 of the Sarbanes-Oxley Act[186](index=186&type=chunk)

PART I – FINANCIAL INFORMATION [Financial Statements (Unaudited)](index=4&type=section&id=Item%201.%20Financial%20Statements%20%28Unaudited%29) Immunome, Inc.'s unaudited condensed financial statements as of June 30, 2022, reflect a **$20.6 million** net loss and **$34.6 million** cash position [Condensed Balance Sheets](index=4&type=section&id=Condensed%20Balance%20Sheets) Total assets decreased to **$39.0 million** by June 30, 2022, driven by reduced cash, while stockholders' equity declined to **$30.3 million** Condensed Balance Sheet Highlights (in thousands) | Account | June 30, 2022 | December 31, 2021 | | :--- | :--- | :--- | | **Assets** | | | | Cash and cash equivalents | $34,649 | $49,229 | | Total current assets | $37,598 | $56,638 | | Total assets | $39,019 | $57,925 | | **Liabilities & Stockholders' Equity** | | | | Total current liabilities | $8,618 | $9,728 | | Total liabilities | $8,742 | $9,740 | | Accumulated deficit | $(99,682) | $(79,105) | | Total stockholders' equity | $30,277 | $48,185 | [Condensed Statements of Operations](index=5&type=section&id=Condensed%20Statements%20of%20Operations) Net loss for the six months ended June 30, 2022, more than doubled to **$20.6 million**, primarily due to increased R&D expenses Statement of Operations Summary (in thousands, except per share data) | Metric | Three Months Ended June 30, 2022 | Three Months Ended June 30, 2021 | Six Months Ended June 30, 2022 | Six Months Ended June 30, 2021 | | :--- | :--- | :--- | :--- | :--- | | Research and development | $5,717 | $3,233 | $13,795 | $5,212 | | General and administrative | $3,209 | $2,507 | $6,785 | $4,425 | | **Loss from operations** | **$(8,926)** | **$(5,740)** | **$(20,580)** | **$(9,637)** | | **Net loss** | **$(8,924)** | **$(5,241)** | **$(20,577)** | **$(9,139)** | | Net loss per share | $(0.74) | $(0.46) | $(1.70) | $(0.83) | [Condensed Statements of Cash Flows](index=7&type=section&id=Condensed%20Statements%20of%20Cash%20Flows) Net cash used in operating activities significantly increased to **$14.4 million** for the six months ended June 30, 2022, reflecting higher net loss Cash Flow Summary (in thousands) | Activity | Six Months Ended June 30, 2022 | Six Months Ended June 30, 2021 | | :--- | :--- | :--- | | Net cash used in operating activities | $(14,436) | $(7,276) | | Net cash used in investing activities | $(176) | $(39) | | Net cash provided by financing activities | $32 | $27,378 | | **Net (decrease) increase in cash** | **$(14,580)** | **$20,063** | [Notes to Condensed Financial Statements](index=8&type=section&id=Notes%20to%20Condensed%20Financial%20Statements) Notes detail the company's biopharmaceutical focus, liquidity challenges, **$99.7 million** accumulated deficit, and DoD contract funding - The company is a biopharmaceutical firm focused on discovering and developing antibody therapeutics for oncology and infectious diseases, including COVID-19[21](index=21&type=chunk) - As of June 30, 2022, the company had an accumulated deficit of **$99.7 million** and expects to generate losses for the foreseeable future[23](index=23&type=chunk)[25](index=25&type=chunk) - Its cash and cash equivalents of **$34.6 million** are expected to fund operations for at least 12 months from the filing date[23](index=23&type=chunk)[25](index=25&type=chunk) - The company has a contract with the Department of Defense (DoD) for its COVID-19 antibody therapeutic, with total funding of **$17.6 million**[58](index=58&type=chunk)[62](index=62&type=chunk) - As of June 30, 2022, **$17.4 million** had been received from the DoD contract[58](index=58&type=chunk)[62](index=62&type=chunk) - The company adopted the new lease accounting standard, ASC 842, on January 1, 2022, resulting in the recognition of a right-of-use asset and lease liability of **$0.2 million**[56](index=56&type=chunk) [Management's Discussion and Analysis of Financial Condition and Results of Operations](index=27&type=section&id=Item%202.%20Management%27s%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations.) Management discusses the company's clinical transition, increased operating losses from higher R&D, and liquidity needs for pipeline advancement [Overview and Lead Programs](index=27&type=section&id=Overview%20and%20Lead%20Programs) The company is a clinical-stage biopharmaceutical firm with lead programs IMM-BCP-01 (COVID-19) and IMM-ONC-01 (oncology) - The company's Phase 1b study of IMM-BCP-01 for patients with SARS-CoV-2 is underway, with topline data anticipated in the second half of 2022[105](index=105&type=chunk) - For the lead oncology program, IMM-ONC-01, the company plans to submit an IND application in the second half of 2022[107](index=107&type=chunk) - The company's discovery engine is expected to advance one to two programs into IND-enabling studies per year[108](index=108&type=chunk) [Results of Operations](index=37&type=section&id=Results%20of%20Operations) Operating expenses significantly increased, driven by an **$8.6 million** rise in net R&D and **$2.4 million** in G&A expenses Comparison of Operating Results (in thousands) | Expense Category | Six Months Ended June 30, 2022 | Six Months Ended June 30, 2021 | Change | | :--- | :--- | :--- | :--- | | Research and development | $13,795 | $5,212 | $8,583 | | General and administrative | $6,785 | $4,425 | $2,360 | | **Total operating expenses** | **$20,580** | **$9,637** | **$10,943** | - The increase in R&D expenses for the first six months of 2022 was primarily due to a **$7.4 million** reduction in contra-R&D expense related to the DoD agreement and a **$1.2 million** increase in personnel costs[136](index=136&type=chunk) - The increase in G&A expenses for the first six months of 2022 was mainly driven by a **$2.3 million** rise in personnel-related costs from increased headcount and stock-based compensation[138](index=138&type=chunk) [Liquidity and Capital Resources](index=41&type=section&id=Liquidity%20and%20Capital%20Resources) The company held **$34.6 million** cash as of June 30, 2022, sufficient for 12 months, but requires additional capital for R&D - The company had **$34.6 million** in cash as of June 30, 2022, which is expected to fund operations for at least 12 months from the filing date[142](index=142&type=chunk)[152](index=152&type=chunk) Summary of Cash Flows (in thousands) | Activity | Six Months Ended June 30, 2022 | Six Months Ended June 30, 2021 | | :--- | :--- | :--- | | Cash used in operating activities | $(14,436) | $(7,276) | | Cash used in investing activities | $(176) | $(39) | | Cash provided by financing activities | $32 | $27,378 | - The company has an Open Market Sale Agreement (ATM) in place, allowing it to sell up to **$75.0 million** in common shares, but has not yet sold any shares under this agreement[142](index=142&type=chunk) [Quantitative and Qualitative Disclosures about Market Risk](index=49&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20about%20Market%20Risk.) As a smaller reporting company, Immunome, Inc. is not required to provide market risk disclosures - As a smaller reporting company, Immunome, Inc. is not required to provide quantitative and qualitative disclosures about market risk[169](index=169&type=chunk) [Controls and Procedures](index=51&type=section&id=Item%204.%20Controls%20and%20Procedures.) Management concluded disclosure controls and procedures were effective as of June 30, 2022, with no material changes - Management concluded that as of June 30, 2022, the company's disclosure controls and procedures were effective[171](index=171&type=chunk) - No material changes were made to the internal control over financial reporting during the quarter ended June 30, 2022[172](index=172&type=chunk) PART II – OTHER INFORMATION [Legal Proceedings](index=51&type=section&id=Item%201.%20Legal%20Proceedings.) The company is not currently involved in any material legal proceedings - The company is not currently involved in any material legal proceedings[174](index=174&type=chunk) [Risk Factors](index=51&type=section&id=Item%201A.%20Risk%20Factors.) As a smaller reporting company, Immunome, Inc. is not required to provide risk factor information - As a smaller reporting company, Immunome, Inc. is not required to provide this information[175](index=175&type=chunk) [Unregistered Sales of Equity Securities and Use of Proceeds](index=51&type=section&id=Item%202.%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds.) No unregistered sales of equity securities or use of proceeds were reported for the period - There were no unregistered sales of equity securities or use of proceeds to report for the period[176](index=176&type=chunk) [Exhibits](index=52&type=section&id=Item%206.%20Exhibits.) This section lists exhibits filed with the Form 10-Q, including corporate governance documents and certifications - Exhibits filed include corporate governance documents, a director compensation policy, and required Sarbanes-Oxley certifications[181](index=181&type=chunk)

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39580 Immunome, Inc. (Exact name of registrant as specified in its charter) Delaware 77-0694340 (State or oth ...